BioTime, Orbit Biomedical to collaborate on OpRegen subretinal delivery for dry AMD

BioTime has entered into a research and option agreement with Orbit Biomedical regarding technology to deliver OpRegen to treat dry age-related macular degeneration, according to a press release.

Under the terms of the exclusive 12-month agreement, the companies will collaborate on the use of Orbit’s injection technology to deliver BioTime’s OpRegen to the subretinal space via a suprachoroidal route in an ongoing phase 1/2 clinical study.

“Orbit Biomedical’s specifically designed device offers surgeons an innovative solution for the delivery of therapies to the subretinal space, a well-known challenge in ophthalmology,” BioTime CEO Brian M. Culley said in the release. “This alliance gives us the opportunity to evaluate the Orbit Biomedical technology early in the clinical development process of OpRegen and also provides BioTime with an option to negotiate an exclusive license for the commercial use of the device with OpRegen for the treatment of dry AMD.”

BioTime has entered into a research and option agreement with Orbit Biomedical regarding technology to deliver OpRegen to treat dry age-related macular degeneration, according to a press release.

Under the terms of the exclusive 12-month agreement, the companies will collaborate on the use of Orbit’s injection technology to deliver BioTime’s OpRegen to the subretinal space via a suprachoroidal route in an ongoing phase 1/2 clinical study.

“Orbit Biomedical’s specifically designed device offers surgeons an innovative solution for the delivery of therapies to the subretinal space, a well-known challenge in ophthalmology,” BioTime CEO Brian M. Culley said in the release. “This alliance gives us the opportunity to evaluate the Orbit Biomedical technology early in the clinical development process of OpRegen and also provides BioTime with an option to negotiate an exclusive license for the commercial use of the device with OpRegen for the treatment of dry AMD.”